Literature DB >> 22571782

Efficient entry to the [2.2.2]-diazabicyclic ring system via diastereoselective domino reaction sequence.

Kaila A Margrey1, Alex J Chinn, Stephen W Laws, Robert D Pike, Jonathan R Scheerer.   

Abstract

A domino reaction sequence involving aldol condensation, alkene isomerization, and intramolecular hetero-Diels-Alder cycloaddition for the synthesis of [2.2.2]-diazabicyclic structures is reported. Excellent diastereofacial control during the cycloaddition is enforced with a removable chiral phenyl aminal diketopiperazine substituent. The reaction sequence rapidly generates molecular complexity and is competent with both enolizable and nonenolizable aldehyde substrates (nine examples total). Progress toward the synthesis of malbrancheamide B, a protypical member of the [2.2.2]-diazabicyclic natural product family, is also disclosed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571782     DOI: 10.1021/ol3007056

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  3 in total

1.  Intermolecular Diels-Alder Cycloaddition for the Construction of Bicyclo[2.2.2]diazaoctane Structures: Formal Synthesis of Brevianamide B and Premalbrancheamide.

Authors:  Jacob G Robins; Kyu J Kim; Alex J Chinn; John S Woo; Jonathan R Scheerer
Journal:  J Org Chem       Date:  2016-02-26       Impact factor: 4.354

2.  A Merged Aldol Condensation, Alkene Isomerization, Cycloaddition/Cycloreversion Sequence Employing Oxazinone Intermediates for the Synthesis of Substituted Pyridines.

Authors:  Jill B Williamson; Emily R Smith; Jonathan R Scheerer
Journal:  Synlett       Date:  2017-02-23       Impact factor: 2.454

3.  Adaptation of a small-molecule hydrogen-bond donor catalyst to an enantioselective hetero-Diels-Alder reaction hypothesized for brevianamide biosynthesis.

Authors:  Daniel J Sprague; Benjamin M Nugent; Ryan A Yoder; Brandon A Vara; Jeffrey N Johnston
Journal:  Org Lett       Date:  2015-01-31       Impact factor: 6.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.